ABBV-744

BD2 domain selective BET inhibitor

orally efficacious in XG w/o platelet, GI tox

from SBDD of BD1/2 dual inhibitors

Nature, 2020, 578, 306-310

AbbVie, North Chicago, IL

ABBV-744 (AbbVie oral in vivo BD2 domain selective BET inhibitor)


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks